PREDILIFE STRENGTHENS ITS ASSETS WITH A NEW AI PATENT

Villejuif, France, May 29, 2024 – PREDILIFE, specialist in artificial intelligence methods for predicting the risks of pathologies, announces the delivery of a patent by the European Patent Office (no. EP3164824) for its method of supervised learning integrated into the MammoRisk® test.

This method, developed in collaboration with Sorbonne University and the Telecom Institute, uses data from 1,700,000 people in France and the United States to estimate the risks of breast cancer. It incorporates risk factors such as age, personal history and imaging parameters, and easily combines with generative AI language models.

Optimized on French data and validated on 1,000,000 American women, this method offers a more precise and flexible prediction than traditional statistical methods. This patent also strengthens the protection of the MammoRisk® software and was valued at €207 million.

Stéphane Ragusa, CEO of Predilife, highlights the importance of this protection for predictive medicine and the intention to deploy this method on different databases for all diseases. This model was selected by the European Union for the MyPeBS clinical trial.